JP2018531609A5 - - Google Patents

Download PDF

Info

Publication number
JP2018531609A5
JP2018531609A5 JP2018521395A JP2018521395A JP2018531609A5 JP 2018531609 A5 JP2018531609 A5 JP 2018531609A5 JP 2018521395 A JP2018521395 A JP 2018521395A JP 2018521395 A JP2018521395 A JP 2018521395A JP 2018531609 A5 JP2018531609 A5 JP 2018531609A5
Authority
JP
Japan
Prior art keywords
nucleic acid
seq
vector
sequence
fxn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018521395A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018531609A (ja
JP6767483B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2016/056572 external-priority patent/WO2017077451A1/en
Publication of JP2018531609A publication Critical patent/JP2018531609A/ja
Publication of JP2018531609A5 publication Critical patent/JP2018531609A5/ja
Application granted granted Critical
Publication of JP6767483B2 publication Critical patent/JP6767483B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018521395A 2015-11-05 2016-11-01 遺伝子療法のための、改変されたフリードライヒ運動失調症遺伝子およびベクター Expired - Fee Related JP6767483B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562251288P 2015-11-05 2015-11-05
US62/251,288 2015-11-05
US201662411980P 2016-10-24 2016-10-24
US62/411,980 2016-10-24
PCT/IB2016/056572 WO2017077451A1 (en) 2015-11-05 2016-11-01 Modified friedreich ataxia genes and vectors for gene therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020156320A Division JP2021019591A (ja) 2015-11-05 2020-09-17 遺伝子療法のための、改変されたフリードライヒ運動失調症遺伝子およびベクター

Publications (3)

Publication Number Publication Date
JP2018531609A JP2018531609A (ja) 2018-11-01
JP2018531609A5 true JP2018531609A5 (enExample) 2019-12-12
JP6767483B2 JP6767483B2 (ja) 2020-10-14

Family

ID=57288476

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018521395A Expired - Fee Related JP6767483B2 (ja) 2015-11-05 2016-11-01 遺伝子療法のための、改変されたフリードライヒ運動失調症遺伝子およびベクター
JP2020156320A Pending JP2021019591A (ja) 2015-11-05 2020-09-17 遺伝子療法のための、改変されたフリードライヒ運動失調症遺伝子およびベクター

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020156320A Pending JP2021019591A (ja) 2015-11-05 2020-09-17 遺伝子療法のための、改変されたフリードライヒ運動失調症遺伝子およびベクター

Country Status (18)

Country Link
US (2) US10548947B2 (enExample)
EP (1) EP3370778A1 (enExample)
JP (2) JP6767483B2 (enExample)
KR (2) KR102200642B1 (enExample)
CN (1) CN108348621A (enExample)
AU (2) AU2016347887B2 (enExample)
BR (1) BR112018007453A2 (enExample)
CA (1) CA2947584A1 (enExample)
CO (1) CO2018004564A2 (enExample)
HK (1) HK1250924A1 (enExample)
IL (1) IL259141A (enExample)
MX (1) MX2018005084A (enExample)
PE (1) PE20181156A1 (enExample)
PH (1) PH12018500964A1 (enExample)
RU (2) RU2021102893A (enExample)
SG (2) SG10201912763QA (enExample)
TW (2) TWI654301B (enExample)
WO (1) WO2017077451A1 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10617770B2 (en) * 2015-04-24 2020-04-14 University Of Florida Research Foundation, Incorporated AAV vector for treatment of Friedreich's ataxia
GB201508026D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Capsid
CN108289932A (zh) 2015-05-22 2018-07-17 D·D·格恩金 胞外dna作为神经变性的治疗靶点
SG10201912763QA (en) * 2015-11-05 2020-02-27 Bamboo Therapeutics Inc Modified friedreich ataxia genes and vectors for gene therapy
US12011488B2 (en) 2016-03-23 2024-06-18 The Regents Of The University Of California Methods of treating mitochondrial disorders
ES3038656T3 (en) * 2016-03-23 2025-10-14 Univ California Methods of treating mitochondrial disorders
EP3491440A4 (en) 2016-09-21 2020-02-26 Commscope Technologies LLC ADAPTER BLOCK ASSEMBLY
BR112019009446A2 (pt) 2016-11-09 2019-07-30 Intrexon Corp construtos de expressão da frataxina
MX2020003042A (es) 2017-09-29 2020-11-18 Voyager Therapeutics Inc Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa.
BR112020006633A2 (pt) 2017-10-03 2020-10-06 Prevail Therapeutics, Inc. terapias genéticas para distúrbios lisossômicos
JP7361037B2 (ja) 2017-10-03 2023-10-13 プリベイル セラピューティクス,インコーポレーテッド ライソゾーム病の遺伝子治療
AU2018346102B2 (en) 2017-10-03 2023-05-11 Prevail Therapeutics, Inc. Gene therapies for lysosomal disorders
CA3079107A1 (en) * 2017-10-17 2019-04-25 Fundacio Institut D'investigacio En Ciencies De La Salut Germans Trias I Pujol Vectors for the treatment of friedreich's ataxia
US11905522B2 (en) 2018-01-16 2024-02-20 Cls Therapeutics Limited Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity
CN112272672A (zh) 2018-04-03 2021-01-26 斯特里迪比奥公司 抗体逃避性病毒载体
CA3094465A1 (en) 2018-04-03 2019-10-10 Stridebio, Inc. Virus vectors for targeting ophthalmic tissues
SG11202009451VA (en) 2018-04-03 2020-10-29 Stridebio Inc Antibody-evading virus vectors
US20210308274A1 (en) * 2018-08-02 2021-10-07 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating friedreich's ataxia
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
JP2021533200A (ja) 2018-08-02 2021-12-02 ダイン セラピューティクス, インコーポレーテッドDyne Therapeutics, Inc. 顔面・肩甲・上腕筋ジストロフィーを処置するための筋標的化複合体およびそれらの使用
CN113166748A (zh) * 2018-08-10 2021-07-23 逻辑生物治疗公司 用于治疗mma的非破坏性基因疗法
SG11202103151RA (en) * 2018-09-28 2021-04-29 Voyager Therapeutics Inc Frataxin expression constructs having engineered promoters and methods of use thereof
EP3880179A2 (en) * 2018-11-14 2021-09-22 Flagship Pioneering Innovations V, Inc. Fusosome compositions for cns delivery
US20220054656A1 (en) * 2018-11-16 2022-02-24 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus for treating pompe disease
JP7704998B2 (ja) * 2018-11-21 2025-07-09 武田薬品工業株式会社 組換えウイルスベクター及びそれの産生のための核酸
KR20210117271A (ko) * 2018-12-21 2021-09-28 노쓰웨스턴유니버시티 근막 손상 예방 및 치료를 위한 아넥신의 사용근각 손상 예방 및 치료를 위한 아넥신의 사용
SG11202110146VA (en) 2019-03-21 2021-10-28 Stridebio Inc Recombinant adeno-associated virus vectors
BR112021019109A2 (pt) * 2019-03-27 2021-11-30 Sigilon Therapeutics Inc Célula rpe manipulada, composições, molécula isolada de dna de fita dupla, dispositivo implantável, cápsula de hidrogel, e, método para aplicar uma terapia com fvii
KR20220004649A (ko) * 2019-03-28 2022-01-11 인텔리아 테라퓨틱스, 인크. 폴리펩티드 발현을 위한 폴리뉴클레오티드, 조성물 및 방법
MX2021012184A (es) 2019-04-10 2022-01-24 Prevail Therapeutics Inc Terapias genicas para trastornos lisosomales.
US20230144548A1 (en) * 2019-06-30 2023-05-11 John Fraser Wright Recombinant aav vectors with altered immunogencity and methods of making the same
WO2021000024A1 (en) * 2019-07-04 2021-01-07 Children's Medical Research Institute Methods and aav vectors for in vivo transduction
CA3147034A1 (en) * 2019-07-12 2021-01-21 Cls Therapeutics Limited Treatment of diseases associated with protein misfolding by nervous system expression of an enzyme which has a deoxyribonuclease (dnase) activity
AU2020346914A1 (en) * 2019-09-13 2022-04-21 Prevail Therapeutics, Inc. Compositions and methods for treatment of Friedreich's Ataxia
EP4045525A1 (en) 2019-10-17 2022-08-24 Stridebio, Inc. Adeno-associated viral vectors for treatment of niemann-pick disease type c
WO2021127533A1 (en) * 2019-12-19 2021-06-24 The Trustees Of The University Of Pennsylvania Compositions for treating friedreich's ataxia
CN113755524B (zh) * 2020-06-02 2023-11-03 舒泰神(北京)生物制药股份有限公司 用于治疗脊髓性肌萎缩的腺相关病毒载体及其用途
EP4188404A4 (en) 2020-07-29 2025-02-26 The Board Of Regents Of The University Of Texas System TRANSGENIC CASSETTES, AAV VECTORS AND AAV VIRUS VECTORS FOR THE EXPRESSION OF HUMAN CODON-OPTIMIZED CSTB
TW202227632A (zh) 2020-08-19 2022-07-16 美商史崔德生物公司 用於治療雷特症候群之腺相關病毒載體
CA3200401A1 (en) 2020-11-03 2022-05-12 Pfizer Inc. Methods for purification of aav vectors by anion exchange chromatography
WO2022137076A1 (en) 2020-12-23 2022-06-30 Pfizer Inc. Methods for purification of aav vectors by affinity chromatography
US20240058477A1 (en) * 2021-01-04 2024-02-22 University Of Florida Research Foundation, Incorporated Methods and compositions for treatment of friedreich's ataxia
WO2022150772A1 (en) * 2021-01-11 2022-07-14 The Trustees Of The University Of Pennsylvania Compositions for treating friedreich's ataxia
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
WO2023114816A1 (en) 2021-12-14 2023-06-22 Neurogene, Inc. Recombinant optimized galc constructs and methods for treating galc-associated disorders
GB202201242D0 (en) 2022-01-31 2022-03-16 Univ Edinburgh Recombinant optimized mecp2 cassettes and methods for treating rett syndrome and related disorders
GB202206336D0 (en) 2022-04-29 2022-06-15 Univ Edinburgh Recombinant therapeutic FMR1 constructs and methods of treating fragile X syndrome and related disorders
WO2024003687A1 (en) 2022-06-28 2024-01-04 Pfizer Inc. Nucleic acids encoding acid alpha-glucosidase (gaa) and vectors for gene therapy
WO2024011109A2 (en) * 2022-07-06 2024-01-11 Adverum Biotechnologies, Inc. Compositions and methods for treatment of achromotopsia
CN117089514A (zh) * 2023-10-13 2023-11-21 思鹏生物科技(苏州)有限公司 提升hek293细胞系aav生产效率的细胞筛选驯化方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
ATE237352T1 (de) 1995-06-07 2003-05-15 Univ North Carolina Helfervirus-freie herstellung von aav
IL128779A0 (en) 1996-09-06 2000-01-31 Univ Pennsylvania Method for recombinant adeno-associated virus-directed gene therapy
AU4645697A (en) 1996-09-11 1998-04-02 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Aav4 vector and uses thereof
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
AU762220B2 (en) 1998-05-28 2003-06-19 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The AAV5 vector and uses thereof
ES2288037T3 (es) 1998-11-05 2007-12-16 The Trustees Of The University Of Pennsylvania Secuencia de acido nucleico del serotipo 1 de adenovirus asociado, vectores y celulas huesped que las contienen.
CA2348382C (en) 1998-11-10 2013-09-17 The University Of North Carolina At Chapel Hill Chimeric parvovirus vectors and methods of making and administering the same
ES2256265T3 (es) 2000-06-01 2006-07-16 University Of North Carolina At Chapel Hill Vectores de parvovirus duplicados.
CA2399576A1 (en) 2000-12-07 2002-06-13 Universite De Nantes Inducible highly productive raav packaging cell-lines
HUE035567T2 (en) 2003-09-30 2018-05-28 Univ Pennsylvania Adeno-associated virus (AAV) clusters, sequences, vectors and applications containing them
NZ555830A (en) 2004-12-15 2009-01-31 Univ North Carolina Chimeric vectors
MX2010002003A (es) * 2007-08-20 2010-03-10 Glaxo Group Ltd Metodo de produccion.
ES2634118T3 (es) 2009-02-11 2017-09-26 The University Of North Carolina At Chapel Hill Vectores de virus modificados y métodos para fabricar y utilizar los mismos
AU2010340358B2 (en) * 2009-12-21 2014-07-24 Pharmathene, Inc. Recombinant butyrylcholinesterases and truncates thereof
EP2539354B1 (en) * 2010-02-08 2017-04-05 The Trustees Of The University Of Pennsylvania Nucleic acid molecules encoding rantes, and compositions comprising and methods of using the same
EP2394667A1 (en) * 2010-06-10 2011-12-14 Laboratorios Del Dr. Esteve, S.A. Vectors and sequences for the treatment of diseases
CA2838588C (en) * 2011-06-09 2021-09-14 Curna, Inc. Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn
EP2771455B1 (en) 2011-10-28 2016-10-05 The University of North Carolina At Chapel Hill Cell line for production of adeno-associated virus
US9066966B2 (en) 2013-02-01 2015-06-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and pharmaceutical compositions for the treatment of cardiomyopathy due to friedreich ataxia
CA2904156C (en) 2013-03-15 2023-01-10 The Children's Hospital Of Philadelphia Vectors comprising stuffer/filler polynucleotide sequences and methods of use
WO2014144229A1 (en) 2013-03-15 2014-09-18 The University Of North Carolina At Chapel Hill Methods and compositions for dual glycan binding aav vectors
CA2907799A1 (en) 2013-05-31 2014-12-04 The Regents Of The University Of California Adeno-associated virus variants and methods of use thereof
CN116004721A (zh) 2013-07-12 2023-04-25 费城儿童医院 Aav载体和用于抗aav(腺相关病毒)中和抗体的检测
SI3024498T1 (sl) 2013-07-22 2020-07-31 The Children's Hospital Of Philadelphia Različica AAV in sestavki, postopki in uporabe za prenos genov v celice, organe in tkiva
EP3459965B1 (en) 2013-10-11 2020-12-02 Massachusetts Eye & Ear Infirmary Methods of predicting ancestral virus sequences and uses thereof
GB201403684D0 (en) 2014-03-03 2014-04-16 King S College London Vector
SG10201912763QA (en) * 2015-11-05 2020-02-27 Bamboo Therapeutics Inc Modified friedreich ataxia genes and vectors for gene therapy

Similar Documents

Publication Publication Date Title
JP2018531609A5 (enExample)
JP2021019591A5 (enExample)
RU2021102893A (ru) Модифицированные гены атаксии фридрейха и векторы для генной терапии
ES2768763T3 (es) Vectores rAAV mejorados y métodos para la transducción de fotorreceptores y células EPR
JP2021106619A5 (enExample)
US7943374B2 (en) Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
JP2020522269A5 (enExample)
US7427396B2 (en) AAV vectors for gene delivery to the lung
JP2021003120A5 (enExample)
FI3684423T3 (fi) Adenoassesioidun viruksen kapsidivariantteja ja niiden käyttömenetelmiä
JP2020096587A (ja) キャプシド
JP2020528734A5 (enExample)
JP2017512466A5 (enExample)
JP2018506261A5 (enExample)
JP2018522529A5 (enExample)
RU2017125234A (ru) Конструкции нуклеиновой кислоты и векторы для генотерапии для применения для лечения болезни вильсона и других состояний
JP7558535B2 (ja) アルデヒドデヒドロゲナーゼ欠損症の治療のための遺伝子治療
TW201629225A (zh) 第九因子基因療法
JP2017529395A5 (enExample)
JPWO2020106916A5 (enExample)
JP2020533276A5 (enExample)
JP2024159800A (ja) 筋肉発現のためのハイブリッドプロモーター
JP2022545121A (ja) Aav5の単離修飾vp1カプシドタンパク質
JP2023538409A (ja) 組み換えaavの作製方法
CA3122319A1 (en) Expression cassettes for gene therapy vectors